Growth peptide release from biologic dressings: a comparison

The Journal of Burn Care & Rehabilitation
H O RennekampffJ F Hansbrough

Abstract

Biologic dressings are believed to stimulate wound healing in a variety of wound types. Cryopreserved allograft skin (CAS) is used as a biologic dressing for excised wounds, partial-thickness wounds, and meshed split-thickness skin grafts, and the use of allogenic or autologous cultured epithelial sheets (CES) has been reported to enhance healing of skin ulcers and deep partial-thickness wounds. However, limitations of allograft skin include bacteriologic and viral safety, limited availability, cost, and ease of handling. Previously we have reported the successful use of human keratinocytes cultured to single-layer confluence on Hydroderm polyurethane membranes (HD/HK) for grafting of full-thickness wounds. In this study we evaluated the release of five different growth peptides (transforming growth factors alpha and beta (TGF-alpha, TGF-beta), interleukin-6, interleukin-8, and melanoma growth stimulatory activity from CAS, CES, and HD/HK grafts. Highest levels of TGF-alpha were found for HD/HK (728 +/- 115 pg/10 cm2 of membrane) followed by CES (491 +/- 137 pg/10 cm2; NS). No TGF-alpha was detectable for CAS, and 3.7-fold, and 25-fold higher levels of interleukin-6 were found for CES (257 +/- 12.7 U/10 cm2) compared with HD/HK...Continue Reading

Citations

Apr 27, 2007·Cell and Tissue Banking·A HautierG Magalon
Oct 13, 2015·Toxicology Letters·Markus WolfAnnette Schmidt
May 14, 2004·The Journal of Investigative Dermatology·Johanna M BrandnerIngrid Moll
Jun 24, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·M MoustafaS MacNeil
Jun 1, 1997·The Surgical Clinics of North America·R J Spence, L Wong
May 5, 1999·Journal of Biomaterials Science. Polymer Edition·M TanakaY Kuroyanagi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.